Phase II Study of the Anti-PD-1 Monoclonal Antibody Pidilizumab (CT-011) with Rituximab for Relapsed FL


Phase II Study of the Anti-PD-1 Monoclonal Antibody Pidilizumab (CT-011) with Rituximab for Relapsed FL
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with Bruce D Cheson, MD (1/14/13)
Westin JR et al. Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma. Proc ASH 2012;Abstract 793.

Dr Cheson is Professor of Medicine, Deputy Chief of the Division of Hematology-Oncology and Head of Hematology at the Georgetown University Hospital Lombardi Comprehensive Cancer Center in Washington, DC.